Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Spero Therapeutics, Inc. (SPRO : NSDQ)

• Company Description    Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. Number of Employees: 32

• Price / Volume Information    Yesterday's Closing Price: $2.48 Daily Weekly Monthly 20 Day Moving Average: 1,018,025 shares Shares Outstanding: 55.91 (millions) Market Capitalization: $138.66 (millions) Beta: 1.33 52 Week High: $3.22 52 Week Low: $0.51 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.65% -19.89% 12 Week 242.07% 197.93% Year To Date 140.78% 124.88%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 675 Massachusetts Avenue 14th Floor - Cambridge,MA 02139 USA ph: 857-242-1600 fax: - ir@sperotherapeutics.com https://sperotherapeutics.com

• General Corporate Information    Officers Esther Rajavelu - Chief Executive Officer; Chief Financial Officer; Milind Deshpande - Director Scott Jackson - Director Cynthia Smith - Director Kathleen Tregoning - Director Peer Information Spero Therapeutics, Inc. (CORR.) Spero Therapeutics, Inc. (RSPI) Spero Therapeutics, Inc. (CGXP) Spero Therapeutics, Inc. (BGEN) Spero Therapeutics, Inc. (GTBP) Spero Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 84833T103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/04/25 Share - Related Items Shares Outstanding: 55.91 Most Recent Split Date: (:1) Beta: 1.33 Market Capitalization: $138.66 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.43 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.10 Price/Cash Flow: - Price / Sales: 3.11 EPS Growth vs. Year Ago Period: -4.17% vs. Previous Quarter: 34.21% Sales Growth vs. Year Ago Period: -36.61% vs. Previous Quarter: -60.95% ROE 06/30/25 - - 03/31/25 - -123.50 12/31/24 - -95.11 ROA 06/30/25 - - 03/31/25 - -58.96 12/31/24 - -48.69 Current Ratio 06/30/25 - - 03/31/25 - 2.56 12/31/24 - 2.19 Quick Ratio 06/30/25 - - 03/31/25 - 2.56 12/31/24 - 2.19 Operating Margin 06/30/25 - - 03/31/25 - -156.48 12/31/24 - -142.91 Net Margin 06/30/25 - - 03/31/25 - -156.48 12/31/24 - -142.91 Pre-Tax Margin 06/30/25 - - 03/31/25 - -156.48 12/31/24 - -142.91 Book Value 06/30/25 - - 03/31/25 - 0.60 12/31/24 - 0.85 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©